globenewswire.com · 6 jul

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

fool.com · 1 jul

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%

It might pull it off, provided several things fall right in place.

benzinga.com · 29 jun

Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.

fool.com · 20 jun

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FDA approval of Yartemlea and a significant development deal with Novo Nordisk.

schaeffersresearch.com · 17 jun

Dow Extends Record Run as Fed Decision Looms

Stocks are mixed, with the Dow Jones Industrial Average (DJI) trading at fresh record highs once again

fool.com · 17 jun

This Stock Is Up 58% This Year. Is It too Late to Buy?

There could be additional catalysts for this drugmaker over the next year.

zacks.com · 16 jun

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.

zacks.com · 16 jun

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.